GLP-1, Syngene & A $20 Billion Dream: Kiran Mazumdar-Shaw Reveals Biocon's Roadmap

Biocon is entering what could be its most important phase yet. In this exclusive conversation, NDTV Profit's Nisha Poddar talks to Biocon Founder & Executive Chairperson Kiran Mazumdar-Shaw at the company's Bengaluru campus to discuss the next chapter of India's leading biotechnology company. From the ambitious goal of building a $20 billion company to the global GLP-1 opportunity, insulin expansion, biosimilars, Singene's turnaround strategy, debt reduction, free cash flow, succession planning, and India's biotech innovation ecosystem—Kiran Mazumdar-Shaw shares her vision for the future in a wide-ranging interview. #biocon #kiranmazumdarshaw #stockmarket #biotech #glp For more videos subscribe to our channel:    / @ndtvprofitindia   Visit NDTV Profit for more news: https://www.ndtvprofit.com/ Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-r... Follow NDTV Profit here Twitter:   / ndtvprofitindia   ,   / ndtvprofit   LinkedIn:   / ndtvprofit   Instagram:   / ndtvprofit   Facebook:   / ndtvprofit